Chinook Therapeutics Announces Upcoming Data Presentations and Investor Conference Call During the American Society of Nephrology (ASN) Kidney Week 2021
- Additional data to be presented from the ongoing phase 1/2 study of BION-1301 in patients with IgA nephropathy, including biomarker and proteinuria reductions
- Several presentations on the atrasentan clinical program, including translational research demonstrating ETA activation is associated with clinical progression in IgA nephropathy
Chinook to host investor conference call and webcast onNovember 4, 2021 to review abstracts and provide updates on the company’s pipeline
ePoster Presentations:
Abstract PO1632 | Pharmacodynamic and Clinical Responses to BION-1301 in Patients with IgA Nephropathy: Initial Results of a Ph1/2 Trial |
Presenting Author | |
Session PO1203-3 | Glomerular Diseases: Treatment and Outcomes |
Abstract PO1633 | Atrasentan Exhibits a Consistent, Predictable Pharmacokinetic Profile Among Healthy Asian Adults |
Presenting Author | |
Session PO1203-3 | Glomerular Diseases: Treatment and Outcomes |
Abstract PO1593 | Precision Medicine Approach Identifies Patients with IgA nephropathy at Risk for Progression Using Endothelin Activation Signatures |
Presenting Author | |
Session PO1203-2 | Glomerular Diseases: Clinicopathological Features and Outcomes in IgAN, Lupus Nephritis, and Vasculitis |
Abstract INFO32 | A Phase 1/2, Multicenter Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BION-1301 in |
Session | Informational Posters: Glomerular Diseases |
Abstract INFO35 | Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atrasentan in Patients with IgA Nephropathy (The ALIGN Study) |
Session | Informational Posters: Glomerular Diseases |
Abstract INFO36 | Atrasentan in Patients with Proteinuric Glomerular Diseases (The AFFINITY Study) |
Session | Informational Posters: Glomerular Diseases |
For more information on these and other abstracts, please visit the ASN Kidney Week 2021 website and Abstract Supplement.
Investor Conference Call Details
To access the call, please dial (844) 309-0604 (domestic) or (574) 990-9932 (international) and provide the Conference ID 1381696 to the operator.
To access the live webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Chinook’s website. The archived webcast will remain available for replay on Chinook’s website for 90 days.
About
Cautionary Note on Forward-Looking Statements
Certain of the statements made in this press release are forward looking, including those relating to Chinook’s business, future operations, advancement of its product candidates and product pipeline, clinical development of its product candidates, including expectations regarding cash forecasts and timing of initiation and results of clinical trials. In some cases, you can identify these statements by forward-looking words such as “may,” “will,” “continue,” “anticipate,” “intend,” “could,” “project,” “expect” or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, including initiation of clinical trials of our existing product candidates or those developed as part of the Evotec collaboration, whether results of early clinical trials or preclinical studies will be indicative of the results of future trials, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that may be more advanced or have greater resources than we do, our ability to obtain and adequately protect intellectual property rights for our product candidates and the effects of COVID-19 on our clinical programs and business operations. Many of these risks are described in greater detail in our filings with the
Contact:Noopur Liffick Vice President, Investor Relations & Corporate Communications investors@chinooktx.com media@chinooktx.com
Source: Chinook Therapeutics, Inc.